SCHEDULE 13D/A Filed 2026-08-10 Event 2026-08-06 SEC 0000947871-26-000776 →

ORBIMED ADVISORS LLC → MBX Biosciences, Inc. MBX

Stake: — Shares: 3,074,853 Class: COMMON STOCK

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

6 transactions

6 buys · 0 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

145 filings by this filer

144 other filings in the data moat

Short Interest · settle 2026-09-30

DTC 6.84

4,466,280 shares short · +8.2% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $21.47M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-06-04	Pescovitz Ora H.	director	Award	12,500	$30.91	$386K
2026-06-04	Heron Patrick J	director, 10%+ owner	Award	12,500	$30.91	$386K
2026-06-04	Stelzer Laurie	director	Award	12,500	$30.91	$386K
2026-06-04	Hoerter Steven L.	director	Award	12,500	$30.91	$386K
2026-06-04	Ryder Steven	director	Award	12,500	$30.91	$386K
2026-06-04	Aynechi Tiba	director	Award	12,500	$30.91	$386K

Other 13D/G Filings on MBX Biosciences, Inc.

Filed	Form	Filer	Stake	Shares
2026-08-10	SCHEDULE 13D/A	Frazier Life Sciences Public Fund, L.P.	—	1,429,573	view →
2026-06-24	SCHEDULE 13G	Paradigm Biocapital Advisors LP	—	—	view →
2025-09-30	SCHEDULE	Frazier Life Sciences Public Fund, L.P.	11.70%	5,224,095	view →
2025-09-30	SCHEDULE	ORBIMED ADVISORS LLC	9.00%	4,002,887	view →
2025-09-30	SCHEDULE	Norwest Venture Partners XVI, LP	4.80%	2,140,989	view →

Other Filings by ORBIMED ADVISORS LLC

Filed	Form	Issuer	Stake	Shares
2026-10-08	SCHEDULE 13D/A	ArriVent BioPharma, Inc.	5.80%	2,875,962	view →
2026-10-02	SCHEDULE 13D	ADARx Pharmaceuticals, Inc.	14.00%	14,913,764	view →
2026-09-25	SCHEDULE 13D	Electra Therapeutics, Inc.	11.00%	6,885,170	view →
2026-09-10	SCHEDULE 13D/A	Braveheart Bio, Inc.	13.50%	12,175,159	view →
2026-08-18	SCHEDULE 13D	BlossomHill Therapeutics, Inc.	8.90%	2,714,279	view →
2026-08-18	SCHEDULE 13D	Braveheart Bio, Inc.	17.20%	12,175,159	view →
2026-08-05	SCHEDULE 13D	Yarrow Bioscience, Inc.	9.97%	266,306	view →
2026-07-29	SCHEDULE 13D	Scribe Therapeutics, Inc.	7.20%	1,348,825	view →
2026-07-20	SCHEDULE 13D/A	Q32 Bio Inc.	—	4,127,987	view →
2026-06-24	SCHEDULE 13D/A	Enliven Therapeutics, Inc. ELVN	—	6,774,507	view →
2026-06-17	SCHEDULE 13D/A	Enliven Therapeutics, Inc. ELVN	10.93%	7,634,630	view →
2026-06-15	SCHEDULE 13D/A	Shattuck Labs, Inc. STTK	—	9,021,127	view →
2026-06-01	SCHEDULE 13D/A	Q32 Bio Inc. QTTB	—	4,127,987	view →
2026-04-10	SCHEDULE 13D/A	Adicet Bio, Inc. ACET	8.80%	844,787	view →
2026-01-27	SCHEDULE	Corvus Pharmaceuticals, Inc. CRVS	10.30%	8,609,091	view →
2025-10-10	SCHEDULE	Adicet Bio, Inc. ACET	9.60%	14,772,598	view →
2025-09-30	SCHEDULE	MBX Biosciences, Inc. MBX	9.00%	4,002,887	view →
2025-07-21	SCHEDULE	Passage BIO, Inc. PASG	7.82%	243,878	view →
2025-05-14	SCHEDULE	Corvus Pharmaceuticals, Inc. CRVS	12.20%	9,785,423	view →
2025-04-11	SCHEDULE	Compass Therapeutics, Inc. CMPX	11.00%	15,219,994	view →

Showing 20 of 144

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →